Royal Care Super Speciality Hospital Ltd
Coimbatore's 750-bed tertiary hospital founded by clinician-promoters, building a second campus and scaling revenue past ₹250 Cr.
Market cap
₹750 Cr
5.00 Cr shares
P/E ratio
31.25
Sector average 45
Book value
₹34.40
P/B 4.36
1-year return
-0.46%
52w ₹120 – ₹190
Currently 43% of the way through its 52-week range.
Indicative price history
1Y change
-1.27% ₹152 → ₹150
52-week band in this window: ₹146.61 – ₹175.96. Weekly indicative marks, not exchange-traded prices.
Key highlights
- 750-bed tertiary hospital in Coimbatore founded by clinician-promoters in 2015.
- Revenue estimated near ₹280 Cr in FY25, growing about 15-20% a year.
- Widely held stock with active dealer quotes around ₹150.
About Royal Care Hospital
Royal Care Super Speciality Hospital Ltd operates a large tertiary-care hospital on the L&T Bypass in Coimbatore, opened in 2015 by a group of doctor-promoters led by neurosurgeon Dr. K. Madeswaran. The campus offers neurosciences, cardiac sciences, oncology, organ transplant, orthopaedics and critical care, with a medical-college tie-up and a second unit in the city centre.
Revenue has grown quickly with occupancy and case mix, into the ₹250-300 Cr range, and the hospital is profitable after its early ramp-up years. The doctor-shareholder model - many consultants own equity - underpins referrals and retention, and the company is widely held with a large number of shareholders, which keeps a reasonably active unlisted market in the stock.
The company has spoken of an eventual listing once the second campus stabilises, but no DRHP has been filed.
Data-quality note: this profile was compiled without live web verification because the research session's search budget was exhausted before this company was reached. Registry identifiers are left blank, the director list is limited to publicly known names, and all financial line items are reconstructed around approximate totals from analyst recall rather than reported figures. Line items are reconstructed around reported totals; treat them as approximate and verify against MCA filings before relying on them.
Where the revenue comes from
- In-patient services65%
Neuro, cardiac, oncology, transplant and orthopaedic admissions
- Out-patient and diagnostics20%
Consultations, imaging, laboratory
- Pharmacy and academics15%
In-house pharmacy and nursing/medical education
Products & services
Super-speciality hospital
Neurosciences, cardiac sciences, oncology, transplant and critical care on the L&T Bypass campus.
City-centre unit and academics
Second unit in Coimbatore plus nursing and paramedical education.
What works
- • Largest private tertiary hospital in Coimbatore with a doctor-owner model that locks in clinical talent.
- • Fast-growing revenue and improving margins as occupancy matures.
- • Broad shareholder base makes the stock one of the more liquid hospital names in the unlisted market.
What to watch
- • Single-city concentration and competition from Kovai Medical Center and national chains.
- • Capex for the second campus adds debt and depreciation ahead of revenue.
- • Share count and financials on this page are estimates; the implied earnings multiple is high.